Zacks Research Issues Pessimistic Outlook for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, May 27th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.17) for the quarter, down from their previous forecast of ($0.13). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.27) EPS and Q1 2027 earnings at ($0.19) EPS.

Other analysts have also recently issued research reports about the company. JMP Securities reissued a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Friday, April 25th. The Goldman Sachs Group reduced their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Finally, Needham & Company LLC cut their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Esperion Therapeutics presently has an average rating of "Hold" and a consensus price target of $6.25.

Esperion Therapeutics Price Performance

ESPR traded down $0.02 during trading on Friday, reaching $0.85. 4,498,295 shares of the stock traded hands, compared to its average volume of 5,455,511. The stock has a market cap of $169.34 million, a price-to-earnings ratio of -1.34 and a beta of 0.75. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $3.94. The stock's 50-day simple moving average is $1.00 and its two-hundred day simple moving average is $1.74.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The company had revenue of $65.00 million during the quarter, compared to analysts' expectations of $54.97 million.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Nuveen LLC bought a new position in shares of Esperion Therapeutics in the first quarter worth about $4,446,000. Wasatch Advisors LP increased its stake in shares of Esperion Therapeutics by 4.9% in the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares during the period. Bank of America Corp DE increased its stake in shares of Esperion Therapeutics by 45.1% in the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares during the period. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.